LGVN Longeveron

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, , and Chief Medical Officer, , will speak on multiple panel discussions at the taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials.

Panel Discussions – December 8, 2025

Cell Therapy Heart Failure Trials – Cells Deliver and Disease Specific Strategies

Is Cell Delivery Route Important?

Intravenous Delivery of Cells/Cell Products: The Magic Bullet? Dr. Joshua Hare

What Type of Cells?

Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON and the PATH AHEAD – Dr. Joshua Hare

How to Streamline Cell Therapy Innovation, Not Compromising the Level of Evidence

The CVCT Multi-Stakeholder Think Tank Debate

Dr. Nataliya Agafonova, Panelist

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit  or follow Longeveron on , , and .

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions

Photos accompanying this announcement are available at





EN
03/12/2025

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dy...

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of lifeFemale sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy womenLongeveron anticipates entering into licensing or partnering agreements for the potential development and commerci...

December 17, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Chief Science Officer and Chief Medical Officer Selected as...

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, , and Chief Medical Officer, , will speak on multiple panel discussions at the taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and ...

December 3, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Granted Canadian Patent for Method of Using Stem Cells to T...

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathyNon-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantationNo approved treatments for aging-related frailty, ...

December 2, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinica...

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple key brain regions, including key Alzheimer’s disease-associated regions, most notably in the hippocampusReduction in hippocampal neuroinflammation, measured ...

December 1, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Post...

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” has been selected for a poster presentation at the 18th to be held December 1-4, 202...

November 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch